<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04158661</url>
  </required_header>
  <id_info>
    <org_study_id>Mya-Thymektomie</org_study_id>
    <nct_id>NCT04158661</nct_id>
  </id_info>
  <brief_title>Influence of Minimally Invasive Thymectomy on the Subsequent Clinical Course of Myasthenia Gravis</brief_title>
  <official_title>Influence of Minimally Invasive Thymectomy on the Subsequent Clinical Course of Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NeuroCure Clinical Research Center, Charite, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Surgery, Charite, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sana Klinikum Lichtenberg, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate whether minimally invasive thymectomy achieves&#xD;
      comparable efficacy and safety results compared to open thymectomy in patients with&#xD;
      myasthenia gravis. The planned investigation is a multicenter observational study based on&#xD;
      retrospective (present patient data) and prospective data (questionable outcome data).&#xD;
&#xD;
      Primary hypothesis: Minimally invasive thymectomy is not inferior to open thymectomy in terms&#xD;
      of efficacy and safety (non-inferiority study).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on large cohort studies of the last decades, the thymectomy has become a central&#xD;
      component of the immunomodulating therapy in MG patients without thymoma detection. Because&#xD;
      randomized studies were missing, remained a residual uncertainty on the importance of&#xD;
      Thymectomy. In the study &quot;Randomized Trial of Thymectomy in Myasthenia Gravis&quot; (MGTX-study)&#xD;
      published 2016 the effectiveness of thymectomy by patients without thymoma detection has been&#xD;
      indisputable confirmed. A significant improvement of the patient's complaints and the&#xD;
      reduction of the immunosuppressive drugs were particularly evident by early onset MG (EOMG)&#xD;
      two to three years after performing a complete resection of the thymic tissue.&#xD;
&#xD;
      While the MGTX study (with an open operative procedure) was being done, the&#xD;
      minimally-invasive thymectomy has gained more and more acceptance. From a surgical point of&#xD;
      view, the minimally invasive thoracoscopic procedure represents a gentler alternative.&#xD;
      According to the momentaneous clinical-scientific point of view, further studies are&#xD;
      necessary to compare both procedures. Furthermore, the MGTX study included only patients with&#xD;
      generalized MG and positive anti-Acetylcholine Receptor (AChR)-antibodies, who were younger&#xD;
      than 65 years, so that the relevance of thymectomy in other important subgroups, such as late&#xD;
      onset MG (LOMG), the ocular MG (OMG), as well as the patients without detected antibodies&#xD;
      (seronegative MG patients), who represent about 10 % of whole population of MG patients, is&#xD;
      still not clear.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean daily prednisone dose</measure>
    <time_frame>three years after thymectomy</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">248</enrollment>
  <condition>Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>Tmin-group</arm_group_label>
    <description>confirmed seropositive ocular or generalized MG [detection of antibodies (Abs) targeting the AChR, muscle-specific tyrosine kinase (MuSK) or Titin] or seronegative ocular or generalized MG&#xD;
age ≥ 18 years&#xD;
thymectomy ≥ three years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T0-group</arm_group_label>
    <description>confirmed seropositive ocular or generalized MG [detection of antibodies (Abs) targeting the AChR, muscle-specific tyrosine kinase (MuSK) or Titin] or seronegative ocular or generalized MG&#xD;
a very long disease history OR&#xD;
age ≥ 18 years&#xD;
rejecting a thymectomy or have contraindications for thymectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MGTX-group (&quot;historical control group&quot;)</arm_group_label>
    <description>from MGTX-trial (&quot;Randomized Trial of Thymectomy in Myasthenia Gravis&quot;)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>thymectomy (robotic-assisted thoracoscopic, minimally-invasive thymectomy)</intervention_name>
    <description>preferring one unilateral access and placing three trocars between 3rd and 5th intercostal space in a triangular configuration, with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).</description>
    <arm_group_label>Tmin-group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>thymectomy by means of median sternotomy (transsternal)</intervention_name>
    <description>with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).</description>
    <arm_group_label>MGTX-group (&quot;historical control group&quot;)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>no thymectomy (control)</intervention_name>
    <description>routine medical care</description>
    <arm_group_label>T0-group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with confirmed diagnosis of myasthenia gravis by:&#xD;
&#xD;
          -  typical clinical features AND&#xD;
&#xD;
          -  antibody diagnostic AND&#xD;
&#xD;
          -  positive edrophonium test OR&#xD;
&#xD;
          -  abnormal repetitive nerve stimulation OR&#xD;
&#xD;
          -  abnormal single-fiber electromyography.&#xD;
&#xD;
        Myasthenia Gravis Foundation of America clinical classification (MGFA classification) of I&#xD;
        to V was accepted (class I indicates weakness only in ocular muscles, class II mild&#xD;
        generalized disease, class III moderate generalized disease, class IV severe generalized&#xD;
        disease and class V a crisis requiring Intubation)&#xD;
&#xD;
        Participants could be taking appropriate anticholinesterase therapy with or without oral&#xD;
        glucocorticoids&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Myasthenia Gravis&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  a proper communication with the patient is not possible&#xD;
&#xD;
          -  an informed consent could not be signed&#xD;
&#xD;
          -  a patient reject a participation or requires breaking up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Meisel, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Surgery Charité University</name>
      <address>
        <city>Berlin-Mitte</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroCure Clinical Research Center (NCRC), Charité University, Berlin</name>
      <address>
        <city>Berlin-Mitte</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sana Klinikum Lichtenberg</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 10.1056/NEJMoa1602489. Erratum in: N Engl J Med. 2017 May 25;376(21):2097. [Dosage error in article text].</citation>
    <PMID>27509100</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Andreas Meisel</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Myasthenia Gravis</keyword>
  <keyword>Robotic-assisted minimally-invasive thymectomy</keyword>
  <keyword>Mean daily prednisone dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

